BioMérieux stock declines and falls back to the bottom of the SBF 120
BioMérieux is falling again on Monday, erasing the technical rebound from the previous session and finding itself at the bottom of the SBF 120 rankings. The decline occurs in a European market that remains broadly stable, with the CAC 40 and SBF 120 trading near equilibrium during the session.
A decline that pushes the stock below its 20-day moving average
BioMérieux is down 2.02% to €72.75 in early afternoon trading, after closing at €74.25 on Friday, September 4. The stock has thus fallen below its 20-day MA at €74.03, deviating by 1.73%, whereas it remained in contact with this threshold during recent sessions. It nevertheless remains slightly above its 50-day MA at €72.14, with a gap of only 0.85%.
The proximity of this 50-day MA warrants monitoring: it is the only short-term support still intact, less than €0.65 below the current price. The RSI at 60 does not yet signal an overbought configuration, but the technical picture is deteriorating: the stock is trading in a narrow corridor between its 50-day MA at €72.14 and its 20-day MA at €74.03. Over one year, performance remains highly negative at -38.5%, and the 200-day MA at €86.63 remains very far above, with a gap exceeding 16%.
A stable SBF 120 that does not offset BioMérieux's weakness over the week
Ranking 107th out of 120 members of the SBF 120, the in vitro diagnostics specialist is among the sharpest declines on the index this Monday, in a session that nonetheless lacks clear direction: the SBF 120 gains barely 0.06% during the session, which makes the relative underperformance of the stock all the more visible. Over the past seven days, the decline reaches 3.32%, while performance over one month remains marginally positive at +0.34%. Analyst consensus on the stock has not been subject to a revision published today. The support level at €69 represents the next level to monitor in case of further decline, with approximately 5% margin relative to the current price.
